Ping An Biomedical Co., Ltd.

Ping An Biomedical Co., Ltd. announced the acquisition of three tumor cell-related medical technology patents from Future Biotechnology Group Co., Limited for an aggregate consideration of $2.3 million. The acquired patents cover areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies. This acquisition is intended to bolster the company's longer-term healthcare and biomedical research and development strategy and establish a core intellectual property portfolio in oncology and biotechnology. Separately, Ping An Biomedical continues to advance negotiations regarding its proposed strategic investment in Future Biotechnology Group Co., Limited.

Ping An Biomedical Co., Ltd. has released its unaudited condensed consolidated financial statements for the six months ended March 31, 2026. The company reported a significant turnaround in profitability, with net income reaching RMB 4.83 million compared to a net loss of RMB 4.23 million in the same period last year. Revenue, however, decreased to RMB 9.59 million from RMB 18.23 million. The company also saw a substantial increase in total assets and a significant boost in shareholders' equity, largely attributed to a private placement. Cash flows from financing activities were strong, reflecting the proceeds from this placement.

Ping An Biomedical Co., Ltd. has formally signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd. Yuan Sheng Mei Yan will act as a channel development service provider, with a shared goal of achieving cumulative sales of RMB 500 million within three years. This partnership aims to leverage Yuan Sheng Mei Yan's health management and customer access capabilities with Ping An Biomedical's biotechnology and R&D strengths to accelerate commercialization and expand market reach.

Ping An Biomedical Co., Ltd.'s wholly-owned subsidiary, Multi Ridge (Asia) Limited, has entered into a Sale and Purchase Deed to acquire Intellectual Property Rights from Meridian Industries Limited. The total consideration for this acquisition is $2,500,000. The payment will be made in two installments, with 90% paid between July 3-9, 2026, and the remaining 10% on the Completion Date of July 10, 2026. The acquisition strengthens Ping An Biomedical's IP portfolio in Hong Kong.

Ping An Biomedical Co., Ltd. announced it received an extension from Nasdaq until November 23, 2026, to regain compliance with the minimum $1 bid price requirement. The company was initially notified of non-compliance on November 24, 2025. Nasdaq's decision for the extension is based on the company meeting other listing requirements and its stated intention to cure the deficiency, possibly through a reverse stock split.